Vulvovaginal pyoderma gangrenosum secondary to rituximab therapy.
Rituximab is being used increasingly for the treatment of B-cell malignancies and nonmalignant conditions. Pyoderma gangrenosum is a rare neutrophilic dermatosis, which can be either idiopathic or associated with underlying systemic inflammatory conditions. We present a series of 4 patients who presented with ulcerative pyoderma gangrenosum in the vulvovaginal area after treatment with rituximab.
1Northern Clinical School, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales; 2Royal Adelaide Hospital, Adelaide, South Australia; and 3Mid North Coast Dermatology, Port Macquarie, New South Wales, Australia.
Shreya
S
Dixit
Priya
P
Selva-Nayagam
Ian
I
Hamann
Gayle
G
Fischer
D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000139:chemically induced* / Q000473:pathology*; D000069283:Rituximab; D014848:Vulvovaginitis / Q000139:chemically induced* / Q000473:pathology*
D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab